K-232 phase 3 comparative study compared to ripasudil ophthalmic solution

K-232 phase 3 comparative study compared to ripasudil ophthalmic solution in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OH)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225065

Enrollment

200

Registered

2020-02-13

Start date

2020-03-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary open-angle glaucoma (broad definition), ocular hypertension

Interventions

investigational material(s) Generic name etc : K-232 INN of investigational material : - Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. POAG (broad definition) or OH patients 2. IOP after ripasudil run-in period => 18mmHg

Exclusion criteria

Exclusion criteria: 1.Patients whose visual acuity is below 0.3 2.Patients thought to use glaucoma medication during this trial 3.Patients thought to wear contact lenses during this trial etc.

Design outcomes

Primary

Measure	Time frame
safety efficacy Efficacy :IOP lowering effect at 4, 6 and 8 weeks (2 hours after instillation) Safety :Incidence of adverse event and adverse drug reaction	—

Secondary

Measure	Time frame
safety efficacy Efficacy :IOP lowering effect at 4, 6 and 8 weeks Safety :Change from baseline in ophthalmologic examination at 8 weeks, etc	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026